News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

iScience Interventional Announces Clinical and Commercial Supply Agreement


10/18/2011 9:56:50 AM

MENLO PARK, Calif.--(BUSINESS WIRE)--iScience Interventional (iScience, Menlo Park, CA), pioneers of site-specific therapies for anterior and posterior ocular diseases, today announced it has signed a clinical and commercial supply agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) and its affiliates. In this agreement, iScience will supply iTrack 275 microcatheters for the delivery of J&JPRD’s cell therapy, CNTO2476, which is currently in clinical trials for the treatment of retinal degeneration.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES